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Abstract
Background: Medication adherence is critical to the effectiveness of psychopharmacologic therapy. Psychiatric disorders
present special adherence considerations, notably an altered capacity for decision making and the increased street value of
controlled substances. A wide range of interventions designed to improve adherence in mental health and substance use disorders
have been studied; recently, many have incorporated information technology (eg, mobile phone apps, electronic pill dispensers,
and telehealth). Many intervention components have been studied across different disorders. Furthermore, many interventions
incorporate multiple components, making it difficult to evaluate the effect of individual components in isolation.
Objective: The aim of this study was to conduct a systematic scoping review to develop a literature-driven, transdiagnostic
taxonomic framework of technology-based medication adherence intervention and measurement components used in mental
health and substance use disorders.
Methods: This review was conducted based on a published protocol (PROSPERO: CRD42018067902) in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses systematic review guidelines. We searched 7 electronic
databases: MEDLINE, EMBASE, PsycINFO, the Cochrane Central Register of Controlled Trials, Web of Science, Engineering
Village, and ClinicalTrials.gov from January 2000 to September 2018. Overall, 2 reviewers independently conducted title and
abstract screens, full-text screens, and data extraction. We included all studies that evaluate populations or individuals with a
mental health or substance use disorder and contain at least 1 technology-delivered component (eg, website, mobile phone app,
biosensor, or algorithm) designed to improve medication adherence or the measurement thereof. Given the wide variety of studied
interventions, populations, and outcomes, we did not conduct a risk of bias assessment or quantitative meta-analysis. We developed
a taxonomic framework for intervention classification and applied it to multicomponent interventions across mental health
disorders.
Results: The initial search identified 21,749 results; after screening, 127 included studies remained (Cohen kappa: 0.8, 95% CI
0.72-0.87). Major intervention component categories include reminders, support messages, social support engagement, care team
contact capabilities, data feedback, psychoeducation, adherence-based psychotherapy, remote care delivery, secure medication
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storage, and contingency management. Adherence measurement components include self-reports, remote direct visualization,
fully automated computer vision algorithms, biosensors, smart pill bottles, ingestible sensors, pill counts, and utilization measures.
Intervention modalities include short messaging service, mobile phone apps, websites, and interactive voice response. We provide
graphical representations of intervention component categories and an element-wise breakdown of multicomponent interventions.
Conclusions: Many technology-based medication adherence and monitoring interventions have been studied across psychiatric
disease contexts. Interventions that are useful in one psychiatric disorder may be useful in other disorders, and further research
is necessary to elucidate the specific effects of individual intervention components. Our framework is directly developed from
the substance use disorder and mental health treatment literature and allows for transdiagnostic comparisons and an organized
conceptual mapping of interventions.
(JMIR Ment Health 2019;6(3):e12493)   doi:10.2196/12493
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Introduction
Background
Medication adherence—the set of behaviors relevant to taking
one’s medication as directed—is critical to the effectiveness of
pharmacologic therapies and improvement of patient outcomes.
Psychiatric and substance use disorders are no exception to this
rule; studies have repeatedly demonstrated the association
between different measures of medication adherence and a wide
variety of psychiatric outcomes. Medication nonadherence
among individuals with schizophrenia has been shown to be
associated with violence [1], hospital admission [2], and
mortality [3]. Among those with mood disorders (eg, major
depressive disorder and bipolar disorder), nonadherence is
associated with hospitalizations, suicide risk, and slower initial
recovery [4,5]. Nonadherence can be particularly problematic
when treating those with opioid use disorders, as it is associated
with treatment dropout [6], which is in turn associated with
continued use of illicit drugs [7] and increased mortality [8].
Such studies strongly suggest the important role played by
medication adherence across psychiatric disorders. The
prevalence of nonadherence in these disorders is also quite high;
studies estimate that 41% to 50% of patients with schizophrenia
[9], 13% to 52% of those with depression [10], 57% of those
with anxiety [11], and 68% of those with opioid use disorder
[12] are not fully adherent to their medication. Outside of
clinical practice, nonadherence and inaccurate adherence
measurement stymie research studies of new interventions;
clinical trials must recruit more participants, spend more money,
and may even produce erroneous results because of
nonadherence [13,14].
Clinicians have been struggling to solve the medication
adherence problem for decades; the body of research conducted
across a wide variety of medical disorders is large and continues
to grow rapidly [15]. The etiologies of nonadherence are
complex and multifactorial; perhaps the most common
framework includes 5 major categories—socioeconomic factors,
health system–related factors, condition-related factors,
treatment-related factors, and patient-related factors [16]. In
psychiatry, the Perceptions and Practicalities Approach classifies
modifiable risk factors of nonadherence into a “ perceptual
category (relating to patient beliefs, eg, about the presence and
severity of their disorder, medication efficacy, and side effect
profile) and a practical category (eg, resources necessary to
acquire medication and cognitive capacity to adhere despite
adequate motivation)—suggesting 2 broad targets for
intervention [17]. Somewhat parallel to this is the distinction
between voluntary nonadherence (eg, due to lack of insight or
desire) and involuntary nonadherence (eg, due to cognitive
limitations, poor understanding, or simply forgetting) [18].
Mental health and substance use disorders present unique
challenges to adherence owing to the nature of the symptoms
associated with these disorders. The delusional belief systems
and poor insight often found in schizophrenia appear to be
associated with lower levels of adherence [9,19]. The street
value of opioid partial agonists (the cornerstone of modern
office-based opioid treatment for opioid use disorders) raises
the specter of medication diversion and provides a strong
incentive for nonadherence. Patients with posttraumatic stress
disorder (PTSD), in particular PTSD induced by medical events,
are more likely to be nonadherent to medication regimens—it
has been proposed that the medications may serve as aversive
reminders that trigger avoidant behaviors [20]. Depressed
patients are much less likely to adhere to medication regimens
[21], likely mediated through a decreased motivation for
self-care [22]. At least one study has linked anxiety disorders
to increased medication nonadherence [23], though other studies
have found mixed results [24]. Across all psychiatric disorders,
the self-stigma associated with receiving treatment for mental
illness has also been shown to contribute to nonadherence [25].
In particular, these challenges may motivate an increased
emphasis on adherence monitoring in addition to adherence
motivation, relative to nonpsychiatric disorders.
In the past few decades, information technology and related
fields have enabled a wide variety of new approaches and
modalities to improve medication adherence and adherence
monitoring. The near-ubiquity of mobile phones [26], the
relative ease of app development, the boom in Internet of Things
devices capable of recording and transmitting real-time
biological data, and the steady improvement of artificial
intelligence (AI) and machine learning systems have all
contributed to this increase in technology-based interventions
for medication adherence.
The field of technological interventions for medication
adherence in psychiatric disorders is quite young and expanding
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in scope, with multiple new trials each year in each disorder
context. Many intervention types have been studied only in pilot
studies, or in randomized controlled trials (RCTs) with small
sample sizes. Furthermore, many interventions consist of
multiple components used in conjunction, which complicates
the study of the efficacy of individual intervention components.
Significant additional research needs to be done before we can
determine which technology-based interventions are most
promising.
Recent related research in summarizing the vast and diverse
field of psychiatric medication adherence technologies includes
systematic reviews focusing on particular disorders such as
mood disorders [27], schizophrenia and other psychotic disorders
[28,29], and substance use disorders [30]. Other reviews evaluate
specific technologic intervention types, including automated
reminders [31], adherence monitoring [32], and virtual reality
technologies [33]. However, given the breadth, size, and
expansion rate of this field, little research has been done to
compare and contrast feasibility and effectiveness of various
interventions across disorder contexts, or to provide a
transdiagnostic framework of adherence intervention
components. Although the efficacy of specific interventions
may ultimately prove to differ between diagnoses, we believe
that the etiologies of nonadherence and the frequently studied
intervention components are similar enough to justify such a
transdiagnostic approach. In this review, we also evaluate this
assumption formally.
Objective
Here, we conduct a systematic scoping review of the literature
concerning technology-based solutions for medication
nonadherence among those with psychiatric disorders. The
review is designed to provide a broad transdiagnostic overview
of research themes and intervention types, with an eye toward
developing a data-driven conceptual framework of
technology-based adherence interventions for mental health and
substance use disorders. We believe that such a framework
would aid researchers in evaluating new literature, create
promising directions for future research, and provide a summary
of this vast field for the busy clinician who may be overwhelmed
by the panoply of available options. In the long term, new
multicomponent interventions might be built quickly and
effectively by sampling promising components from this
framework, based on domain-specific knowledge from a
researcher or clinician’s area of study.
Methods
Overview
This is a systematic scoping review of technological
interventions designed to improve medication adherence in
mental health and substance use populations. We define
technology broadly, including software, hardware, algorithms,
and biosensors. This review was conducted based on a published
protocol (PROSPERO: CRD42018067902). We conducted a
qualitative synthesis of themes in the included literature,
constructed graphical concept maps and graphed topic area
popularity over time in different psychiatric disorder contexts.
We aimed to provide a comprehensive transdiagnostic
framework with which to think about and categorize components
of technological interventions for medication adherence in
mental health and substance use populations.
Search Strategy
To obtain relevant scientific literature, we searched 7 electronic
bibliographic databases: MEDLINE, EMBASE, PsycINFO, the
Cochrane Central Register of Controlled Trials (CENTRAL),
Web of Science, Engineering Village, and ClinicalTrials.gov.
Study records identified from ClinicalTrials.gov were used to
search for related published articles and conference proceedings.
Reference lists from the included studies as well as reviews on
related topics were searched for additional relevant articles.
Authors were contacted to answer specific questions when
necessary.
Using the Population-Intervention-Comparison-Outcome (PICO)
framework [34], 3 core thematic concepts were used to build
the search strategy: mental health and substance use disorders
(population), technology (intervention), and medication
adherence or compliance (outcome); all 3 of which were
necessary for article inclusion. We constructed the final search
strategy through an iterative collaborative process, which
included reading related review articles, building a tree of
relevant MeSH terms, and testing searches against a growing
corpus of ”must-include“ articles identified through a
preliminary search. Furthermore, we consulted with multiple
research librarians to ensure our strategy was comprehensive
and database-specific.
We searched by title or keyword, using MeSH terms for
MEDLINE and analogous terms for other databases when
applicable (eg, Emtree). We initially included English language
articles published between January 2000 and January 2018;
articles from before 2000 were unlikely to be relevant from a
technological perspective. Reviews, letters, case reports,
editorials, and other forms of nonprimary research were
excluded. Journal articles, conference proceedings, and abstracts
were included if they represented primary research. Given the
broad scope and heterogeneity of the topic, we included all
study designs, ranging from RCTs to pilot feasibility studies to
provide a comprehensive concept map. For completeness, a
search for any updated manuscripts was rerun on MEDLINE,
EMBASE, PsycINFO, CENTRAL, and Web of Science during
September 2018. The full search strategies are listed in
Multimedia Appendix 1.
Inclusion Criteria
Adherence
Much of the literature around technological adherence
interventions relates to improving the accuracy of adherence
measurement (eg, ingestible biosensors, smart pill bottles, and
directly observed remote medication ingestion). Accurate
adherence measurement is critical for evaluating the efficacy
of interventions both in clinical practice and in research studies,
it and is a critical part of many multicomponent interventions.
We therefore considered a study to meet the adherence criteria
of inclusion if the intervention was designed to improve either
medication adherence or the accuracy of adherence
measurement. We excluded articles which evaluated participant
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adherence to the intervention as a whole, or a component of the
intervention other than adherence to pharmacologic therapy (for
instance, a study evaluating whether participants were adherent
to a Web-based psychoeducational program). Articles that did
not directly measure medication adherence or medication
adherence measurement accuracy as an outcome (eg, pilot
feasibility or usability studies) were included if medication
adherence was a key motivating factor for development of the
intervention, as assessed by the abstract, introduction, and
discussion sections of the article.
Technology
Given the aim of the scoping review, we defined technology as
broadly as possible. We wanted to include all forms of modern
information technology such as mobile phones, mobile apps,
websites, and computer vision-based (CV) AI systems, as well
as interactive voice response (IVR) technology. Furthermore,
physical technology such as smart pill bottles and ingestible
sensors, as well as studies of novel biomarkers or biological
measurement methods, were considered to meet the technology
criterion for inclusion. Many of the multicomponent
interventions found throughout the course of the search
contained some technological components while also containing
other components that did not meet our definition of
technology-based; we included these studies and will describe
the technological components therein to provide the most
comprehensive map of the space.
Other Exclusions
We excluded articles that did not exclusively study a psychiatric
or substance use population (although we did include articles
in which all the participants had an additional nonpsychiatric
condition—eg, patients with HIV and opioid use disorder). We
excluded epidemiologic studies that only examined the
prevalence of nonadherence. We excluded studies which
provided only financial incentive for medication adherence with
no other components. We excluded protocol-only articles if
outcome articles were available for the same study. We excluded
articles focusing on pediatric populations, as their caretakers
are often responsible for their adherence behaviors. Similarly,
we excluded studies of patients with dementia disorders, as they
often have caretakers who are responsible for adherence
behaviors.
Study Selection and Extraction
We used the Cochrane Covidence tool [35] to assist in
conducting most of the systematic review. To be included, an
article had to be deemed relevant at 2 stages—1) title and
abstract screen and 2) full-text screen. Overall, 2 reviewers (JMS
and NG) independently screened each abstract and full-text
article. Conflicts were resolved via discussion until consensus
was reached; a third reviewer (JB) was on hand to resolve
disagreements, but this was not needed for this review. Interrater
reliability was calculated for both the title-abstract stage and
the full-text screening stage using Cohen kappa.
Included articles were then extracted using a charting tool
developed iteratively by the authors. Both reviewers (JS and
NG) performed extraction on each of the articles and compared
the extracted results. Extracted data fields included the
following: author’s name, year of publication, study objectives
(primarily targeted at improving adherence, measurement
accuracy, or both), population (eg, opioid use disorder or bipolar
disorder), study type (eg, RCT or pilot feasibility), study size,
components of intervention delivered technologically (eg,
reminders, education, support, or monitoring), and technological
modality when applicable (eg, app, website, or IVR). We did
not assess risk of bias or study quality given the large amount
of heterogeneity in study populations, study designs, intervention
types, and outcome measures as well as the goal to conduct a
systematic scoping review.
Before starting the review, we chose to make a top-level
distinction between data collection components (system
components designed to collect data or improve the accuracy
of adherence measurement) and interventional components
(system components designed to directly increase medication
adherence).
Results were labeled as including a data collection component
if the study either (1) evaluated the accuracy of a measurement
method (for instance, a study which compared clinician ratings
of adherence to electronic pill monitors) or (2) evaluated an
interventional system which periodically assessed participant
adherence as part of the intervention, not merely a study
endpoint (eg, a mobile phone app which notifies clinicians in
real time of nonadherence events and encourages them to
intervene would count as a ”data collection” intervention, but
an RCT which evaluated the effects of a psychoeducational
program on adherence using electronic pill monitors merely as
an endpoint would not fall under this category).
Synthesis
For this scoping review, we performed a qualitative synthesis
of the included studies. We categorized the studies by study
type, intervention type, population studied, and technological
modality. We created a hierarchical taxonomy of intervention
components.
Results
Study Selection and Extraction
The literature search identified 21,749 results. A search of
related reviews and references in relevant articles did not find
any additional results. Of these, 3955 duplicates were removed,
and 17,542 results were excluded based on the title and abstract,
yielding 252 results (Cohen kappa before reconciliation=0.82,
95% CI 0.78-0.86). These were screened based on their full
texts, and 125 were excluded (Cohen kappa before
reconciliation=0.80, 95% CI 0.72-0.87). This left a total of 127
articles and conference proceedings that met the inclusion
criteria (Figure 1). In the final rerun of the search in September
2018, 3 indexed manuscripts were found that replaced
conference proceedings describing the same studies. All included
studies are provided in Multimedia Appendix 2.
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses Diagram of included studies.
There was an increase over time (2000-2018) in the prevalence
of included articles. The graph showing the number of included
articles per year is given in Figure 2. As the amount of total
published research has also increased over this same time span,
we provide in Figure 3, a graph relative to the total amount of
published research in MEDLINE. Each data point is calculated
by dividing the number of included articles from a given year
by the number of total MEDLINE articles published during that
same year (based on MEDLINE’s “Publication Date” field).
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Figure 2. Included articles by year.
Figure 3. Included articles by year, divided by total number of MEDLINE articles published during that same year.
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Characteristics of Included Studies
Of the included studies, 40.2% (51/127) were RCTs; 56.7%
(72/127) implemented nonrandomized interventions (eg,
nonrandomized multiarm studies, single-arm studies, pilot
feasibility studies, comparison of multiple measurement methods
in 1 group, etc). The remaining 4 [36-39] were surveys or focus
groups of potential participants evaluating participant
willingness to use specific interventions.
Many psychiatric populations were studied (Figure 4): primary
psychotic disorders (n=39), substance use disorders (n=36),
major depression (n=20), bipolar disorder (n=9), attention deficit
hyperactivity disorder (ADHD; n=2), and PTSD (n=2). Common
transdiagnostic populations included “schizophrenia or bipolar
disorder” (n=8), dual diagnosis (substance use disorder comorbid
with a primary psychiatric disorder, n=3), and pandiagnostic,
that is, any psychiatric disorder (n=6). The remaining studies
evaluated all patients taking aripiprazole [40] or pooled data
from multiple clinical trials of medications for schizophrenia
and ADHD [41]. Among the substance use disorders, tobacco
was studied most (n=15), followed by opioids (n=11), alcohol
(n=5), cannabis (n=2), amphetamines (n=2), and all substance
use disorders (n=1).
Studied outcomes included intervention feasibility (n=29),
system usability (n=12), and participant satisfaction or
acceptability (n=38). Furthermore, 94 studies included some
measure of medication adherence, and 32 evaluated or compared
the accuracy of one or more medication adherence measurement
methods. Many studies evaluated other outcomes, including
change in symptoms over time, reduction in substance use, or
physiologic metrics such as sleep duration or step count.
Synthesis
On the basis of the included articles, we constructed a taxonomy
of components of the studied technological systems, broken
down into the 2 major categories of “data collection
components” and “interventional components.” Note that any
particular study or technological system may include
components from one or both categories. A concept map of the
full taxonomy is provided in Figure 5.
Figure 4. Number of articles by diagnosis. ADHD: attention deficit hyperactivity disorder.
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Figure 5. Visual concept map of components of studied technological systems. GPS: global positioning system.
A. Data Collection Components
Adherence measurement and monitoring are critical components
of adherence enhancement in many ways, from accurately
evaluating the efficacy of interventions designed to improve
adherence to identifying patients who would benefit from
adherence interventions. The majority of studies collected only
adherence data, however, we also included a collection of
related data within this category (A.9.). This reflects the group
of technological systems that collect data other than adherence
for downstream use in interventional components.
A.1. Patient Self-Report
By far, the most commonly studied method (n=54) for measuring
medication adherence was patient self-report. Many
multicomponent apps or websites included daily or weekly
surveys filled out by the participants; self-report of medication
adherence was frequently included in these surveys [42-48];
IVR, telephone, text messaging, and videoconferencing
interventions similarly included questions evaluating medication
adherence [49-55]. Furthermore, self-report was frequently used
as a baseline adherence assessment method with which other,
more objective measures were compared [56-59].
A.2. Care Network Report
Some studies evaluated the subjective overall adherence report
by individuals other than the participant (eg, treating clinicians
or participant’s friends, family, or other social support). These
reports were not based on direct observation, but rather on
subjective, retrospective assessments of a patient’s adherence
history or an overall perception of their likelihood to be
adherent. This method was rarely used; none of the included
studies included it as part of an adherence intervention.
However, 6 studies evaluated its accuracy compared with other
measurement methods [56-58,60-62]. All 6 studies evaluated
1-time subjective clinician rating scales, and 2 also evaluated
reports from a “relative” or a “close informant” [58,62].
A.3. Direct Visualization of Medication Ingestion
Many interventions attempted to confirm adherence by directly
visualizing the process of medication administration. Although
there were many types of direct visualization methods, all of
them involved observation of the patient during the process of
physically ingesting the medication.
A.3.1: Human Observation, Synchronous
Direct visualization of medication ingestion in real time by a
human observer was studied in 4 interventions. A total of 2
studies used direct in-person observation as a gold standard to
evaluate the accuracy of other measurement systems (A.3.1.1)
[63,64], whereas 2 other studies used mobile videoconferencing
technology to observe dosing remotely (A.3.1.2) [65,66]. Both
of these studies had a standardized protocol for observed dosing,
ostensibly to ensure adherence; the participants kept the pill
container on camera while removing the medication and showed
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their open mouth following pill ingestion to prevent hiding the
medication in the cheek.
A.3.2. Human Observation, Asynchronous
A related method of visual adherence measurement, studied by
4 included articles, involved the participant capturing static
photos or videos of the medication dosing process, to be
evaluated in nonreal time (n=4). One study [38] evaluated the
acceptability of static photos of pill counts (A.3.2.1) among a
population of patients on buprenorphine. A total of 2 other
studies discussed daily photographs of individual medication
doses taken at the time of ingestion, either as the only
intervention [67] or as part of a multicomponent intervention
app [68]. Moreover, 1 study discussed nonreal-time video
footage (A.3.2.2) captured on mobile phones as an adherence
measurement method [69].
A.3.3. Computer Observation (Fully Automated)
Overall, 2 included studies evaluated the feasibility, usability,
and measurement efficacy of AICure (AICure, LLC), an
automated form of direct observation using CV algorithms to
confirm pill ingestion in real time without a human observer
[41,64]. The platform worked by automatically identifying the
patient and drug in real-time video footage taken on mobile
devices to confirm ingestion.
A.4. Biomarkers and Metabolites
In current clinical practice, measurements of concentrations of
medications or medication metabolites in body fluids such as
urine or serum are frequently used to assess compliance with
the medication. A total of 15 of the included studies either
included such measurements as part of a multicomponent
intervention [70,71], used serum (A.4.1) or urine (A.4.2)
measurements as a gold standard comparator for other adherence
measurement approaches [58,64,72], or evaluated a novel system
for biological confirmation of adherence. Such systems included
measurements from breath (A.4.3) [73,74], oral fluid (A.4.4)
[75,76], hair (A.4.5) [77-79], and skin (A.4.6) [80]. Overall, 1
study evaluated the accuracy of urine systems for an
experimental cannabinoid [81]. Another study proposed a system
of quantitative serum drug monitoring for all psychiatric
medications to track adherence and better achieve therapeutic
levels [82].
A.5. Smart Pill Containers
“Smart” pill containers using digital information technology to
measure adherence (eg, Medication Event Monitoring System
[MEMS]) were well-represented among the included studies.
Most of these systems used electronic components in the cap
to detect the opening of the pill bottle. Data were either
wirelessly transmitted to a central server periodically or were
retrieved from the bottle at clinic visits. A total of 34 studies
directly used such a pill container as part of an intervention or
evaluated the accuracy of adherence measurement through such
a system [56-62,67,70,71,83-106]. The MEMS was by far the
most widely used, but variations on it, including a nasal spray
monitor [86], were also used. A total of 19 included studies
examined antipsychotic medication adherence, 10 studied
substance use disorders, and the remaining 3 studied mood
disorders. Many more studies used the MEMS as the endpoint
measure for an adherence-enhancing intervention.
A.6. “Smart” or Digital Pill
A total of 5 studies evaluated the efficacy of a “digital pill” or
“digital medicine system” which, upon gastric activation,
transmitted a signal to a wearable sensor which then uploaded
data to a central server. All of the studies were conducted with
antipsychotics meant to be used long term [40,63,107-109].
A.7. Pill Counts
One common low-cost method of medication adherence
measurement involved single-time counting of pills remaining
in a container, either in-person or remotely over
videoconferencing software. Pill counts were used (n=12) either
as one component of a multicomponent adherence-enhancing
intervention or in comparisons of adherence measurement
methods [56-59,66,67,70,71,89,96,104,110]. We did not include
studies that merely used pill counts to evaluate a study endpoint.
A.8. Drug Utilization Measurements
Finally, objective measurements such as pharmacy refills (A.8.1)
or insurance claims (A.8.2), which do not directly capture
medication administration data but may provide indirect indices
of medication possession and adherence, have been used to
assess adherence behaviors over the long term (n=3). Overall,
2 studies calculated medication possession ratios and used them
in feedback interventions to enhance as well as measure
adherence: one with antipsychotics [111] and one with PTSD
medications [112]. Another study incorporated barcodes attached
to pill containers (A.8.3). Participants scanned these codes with
their mobile devices upon receiving the pill containers, allowing
for another form of pickup-level verification [68]. Pill count
(eg, observing how many pills were left in the container) was
another commonly (n=12) used component either in
multicomponent adherence-enhancing interventions or in
comparisons of adherence-monitoring methods.
A.9. Collection of Adherence-Related Data
It was common (n=46) for interventions to collect and track
adherence-related data other than medication adherence itself
(eg, symptoms and health care utilization) for a variety of
downstream uses. As with adherence measurement, we excluded
interventions that tracked other data for the purposes of
evaluating study endpoints but did not use the data in the
intervention itself. Data collection modalities included mobile
apps, Web forms, phone calls, IVR, one-way text messages,
and smart pill dispensers [90]. Most of the data were used in
clinician monitoring or alert systems, but some were used to
tailor patient-specific motivational therapy (eg, in handling
specific drug use triggers in substance use disorders) [113,114].
By far, the most commonly collected data were basic psychiatric
symptom assessments (A.9.1), for example, early warning signs
of psychosis [105], illicit drug cravings [115], withdrawal
symptoms [70,90], mood [107,116], or PTSD symptoms [112].
Other studies tracked attitudes toward medication [117] or
medication side effects [118,119] to guide motivational
interventions (A.9.2). Others tracked potential triggers or indices
for relapse likelihood including stress, anxiety, sleep, and social
support [42,44,120]. Some tracked health care utilization
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metrics, such as primary care visits attended, specialty care
referrals followed, and medication changes made (A.9.3)
[121,122]. A total of 3 studies [42,116,123] collected real-time
global positioning system information through mobile phones
(A.9.4); in one of the studies, redirection alerts were provided
when patients entered previously assigned high-risk areas [123].
Some studies allowed for free text entry by the participant in
the form of online journals which could later be viewed and
correlated with adherence and symptomatic data (A.9.5) [42,47].
B. Adherence-Enhancing Interventions
Any technological component not designed directly to improve
medication adherence monitoring accuracy was classified as an
“adherence-enhancing” intervention. Generally speaking, these
components were designed to enhance a participant’s motivation
(eg, motivational intervention or psychoeducation) or ability
(eg, reminders or social support engagement) to adhere to
pharmacologic therapy.
B.1. Reminders
Reminders directed participants to take their medication as
prescribed (n=25). Most of these studies (n=14) used short
messaging service (SMS) messages sent to a participant’s mobile
phone [36,37,39,54,87,124-132]. Usually, these were
prespecified reminder messages programmed to be sent at
specific times, but some studies examined the use of
personalized SMS reminder messages sent by another person,
either a “treatment partner” from the community [36] or a social
worker [54]. Other messages included reminders delivered as
programmatic app notifications, which functioned similarly to
SMS reminders [43,52,68,91,118] and often comprised one
aspect of multicomponent app interventions. Still other
interventions used smart pill containers as the vehicle for
reminder delivery—one smart dispenser uses visual and sound
alarms to alert the participant when it is time to take medication
[95,98], and another similarly uses audio alarms which can be
silenced by pressing a button on the pill dispenser [96,105].
Email [45] and an unspecified social media reminder [133] have
also been used.
B.2. Supportive Messages
Some interventions (n=21) included supportive one-way
messages delivered through SMS, IVR, telephone call, or mobile
app, which encouraged or motivated the participant. Some used
inspirational quotes such as “The journey of a thousand miles
starts with a single step” [49], whereas others displayed the
length of successful adherence [68], encouraged continued
engagement with the platform [113], or provided encouraging
health facts, for example, “Today your blood pressure has been
reduced to that of a nonsmoker” [134]. Most were generated
and sent or displayed automatically [37,114,123,127,
133,135-137], but others were sent as part of a standardized
protocol by care team members [53] or lay health support
persons [138], or in response to specific behaviors such as
persistently elevated adherence [54,118,139] or positive
responses to therapeutic questions [55]. Automated relational
agents performed this behavior as part of a larger conversation
[140,141]. One focus-grouping study found that participants
would like to receive personalized self-efficacy messages [39].
B.3. Social Enhancement Interventions
This general category focused on leveraging existing social
support or building new social support networks for participants.
B.3.1. Engaging Existing Social Support
Technological interventions focused on engaging patients’ social
support systems (friends, family, etc) in their care were prevalent
(n=9). One study focus-grouped an intervention involving a lay
“treatment partner” sending SMS antipsychotic adherence
reminders to keep the participant engaged in care [36] . Another
study used an online social network intervention to allow former
smokers to support current smokers in adhering to their nicotine
replacement therapy and promoting cessation [142]. An
automated “conversational agent” encouraged participants in a
study of individuals with schizophrenia to recruit a specific
member of their social network to provide reminders and
logistical support (eg, transportation problems) and later
referenced this social support in future conversations [140],
whereas a telephone and Web-based intervention encouraged
participants to find and contact social supports [142]. Other
interventions incorporated a lay health supporter as a recipient
of other technological interventions such as psychoeducation
[143] or adherence reminder systems and data-gathering surveys
[125]. Still others [125,138,144,145] looped social support into
the intervention by sending them automated periodic progress
reports on adherence and symptomatic control and encouraging
the social support to reach out to the participant depending on
the gathered data. One study allowed participants to choose
weekly support phone calls with a family member or friend
[145] versus a trained peer support specialist and compared
outcomes.
B.3.2. Building New Social Support
A total of 6 studies focused instead on building new social
support structures for participants. All 6 included online
discussion forums or groups where participants could discuss
a variety of treatment or adherence-related issues
[42,47,123,142,146,147], and all were part of multicomponent
interventions. One study [142] included a complete social
network of former and current smokers with member profiles
and private messaging in addition to public forum posts.
B.3.3. Relational Agent
A total of 2 studies evaluated the use of “embodied relational
agents” as adherence aids [140,141] in schizophrenia treatment.
These relational agents were computer-generated animated
humanoid figures who interacted through scripted modules and
programmed response trees, allowing for limited bidirectional
communication with the participant. The included studies that
evaluated relational agents used the agents as a general purpose
treatment delivery modality, incorporating psychoeducation,
adherence measurement, symptom assessment, behavioral
counseling, encouragement, and general purpose social support.
B.4. Facilitating Care Team Access
Some adherence interventions (n=13), in particular mobile phone
and Web apps, included functionality for the participant to
initiate contact with a care team representative at any time. Some
[118] allowed the sending of prespecified messages regarding
side effects or symptoms or had the study staff screen messages
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meant for the clinical care team [128,129], whereas others
allowed for general purpose two-way messaging through SMS,
email, or a messaging system designed separately for the app
[42,45,53,65,114,139,147]. Another stored care team contact
information within a multicomponent app to enable one-button
contact, and displayed this button based on certain user
responses [68]. One study collecting adherence data via IVR
allowed participants to be transferred to a case manager during
the IVR call [148], and another evaluating text message content
preferences among potential participants receiving
buprenorphine maintenance treatment found that they would
prefer frequent provider contact to be available [39].
B.5. Data Feedback
This component of interventions was designed to present
collected data on medication adherence or adherence-related
data to users of the system, including participants, clinicians,
or both. Participant feedback was designed to enhance
self-knowledge and accountability, whereas clinician feedback
enabled monitoring of patient adherence, as well as early and
targeted intervention in the case of nonadherence or other
treatment concerns.
B.5.1. Patient-Directed Feedback
Medication adherence feedback directed toward patients was
used in 25 studies. This category included any intervention
component which enabled the participant to view their own
adherence data, either in real time through a mobile phone or
website interface or via periodically generated reports.
Frequently, this was one part of multicomponent interventions,
but some studies evaluated the effect of feedback alone as an
adherence-enhancing intervention [84,85,88,102,103]. Other
systems included feedback on more than just adherence data
(eg, symptomatic progression as assessed by self-report)
[44,46,120]. Note that accurate medication adherence feedback
rests on the assumption of an accurate measurement method.
B.5.2. Clinician-Directed Feedback
Various systems were developed to keep treating clinicians
informed about medication adherence and other related data, to
enable earlier and more accurate identification of potential issues
for intervention. The data given to the clinician was sourced
from many of the previously listed medication measurement
components (direct visualization, smart pill dispenser,
self-report, etc). Multiple studies (n=31) explicitly mentioned
such systems [40,42,44-46,49,51,53,63,65,91,93,95,104,105,
107,108,111,112,114,116,118-120,123,125,138,139,144,145,147],
which fell under 3 major categories (not mutually exclusive):
“portal” real-time monitoring (n=15), periodic reporting (n=9),
and alerts (n=16). Real-time monitoring (B.5.2.1) allows the
clinician to, at any time they choose, examine their participants’
medication adherence data, almost always through Web portals
[40,44-46,63,65,95,104,105,107,108,116,118,120,147]. Periodic
reporting (B.5.2.2) involves standard adherence reports sent at
regular intervals, most often through emails [49,51,91,93,
111,125,139,144,145]. Alerts (B.5.2.3) are “push” notifications
sent to notify clinicians in circumstances that require immediate
response, such as suicidal ideation, hospitalization, and life
disturbances such as housing eviction, physical side effects (eg,
chest pain), or relapse to drug use [42,44,51,53,65,104,
105,108,111,112,114,119,123,138,144,145]. In some studies,
patients’ social support as well as the clinical care team was
able to receive reports or alerts [53,125,138,144,145].
B.6. Passive Education
Educational interventions were present in 39 included studies
[42,45,47,51,64,68,70,71,84,88,91,93,102,105,113,114,
118,123,127,130,134,136,137,139-142,146-157]. Modalities
included websites, mobile apps, telephone calls, SMS messages,
IVR calls, relational agents, and smart pill dispensers. Frequently
presented educational topics included the studied disorder (eg,
chronicity, symptom management, triggers, and warning signs),
the studied medications (eg, purpose, onset of action, and
possible side effects), strategies to improve medication
adherence (eg, routines and planning for potential barriers), the
importance of medication adherence, coping strategies for
setbacks, and the importance of social support. In the vast
majority of studies, education was one component of a
multicomponent intervention.
B.7. Comprehensive Mental Health Care
Many studies (n=22) evaluated medication adherence in the
context of remotely delivered psychiatric or mental health
care—defined for the purposes of this study as when normal
components of mental health care visits (cognitive behavioral
therapy [CBT], symptomatic check-ins, and medication
adherence counseling) were delivered remotely, through phone
calls or videoconferences, by members of the care team
including psychiatrists, nurses, pharmacists, and specialized
coaches. Some of the studies compared medication adherence
(and other outcomes) between telecare and care as usual
[158-161], whereas others evaluated the effects on adherence
of novel standardized intervention protocols delivered over
telephone or videoconference [50,53,65,96,112,115,119,122,
127,143,146,149,152,154-157,162]. The content of novel
protocols varied widely, but frequently focused on disease or
medication education, symptomatic assessment, and
motivational enhancement around medication adherence.
Overall, 6 explicitly referenced motivational interviewing
[65,112,127,146,149,156] and 3 drew from CBT [127,143,149].
Frequency ranged from daily to monthly. Some were part of
multicomponent technological interventions [65,96].
B.8. Adherence-Targeted Interactive Psychotherapy or
Counseling
Some interventions used technology to deliver
adherence-focused psychotherapy or counseling, either remotely
as part of remote care or as part of a standardized intervention
delivered through an app or a website. One major modality
which emerged was motivational intervention around medication
adherence (n=9). This was used in remote psychiatric care in
the aforementioned 6 studies [65,112,127,146,149,156], but it
was also used without a human clinician in 3 mobile phone apps
or Web-based interventions [42,47,118]. In one study, the patient
was queried about their reasons for nonadherence and, based
on the reasons, was provided with tailored motivational feedback
[118]. In the others, the cost-benefit framework was used within
the website to encourage the participant to evaluate strategies,
solve problems, and set goals [42,47]. The other major
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framework which emerged (n=12) was CBT, which is used as
a major component of psychotherapy in many of the studied
disorders and can help restructure maladaptive thoughts about
psychoactive medication. In the included studies, strategies
from CBT were used as part of tele-mental health care
[127,143,149], as the comparator [84], or as part of Web or
mobile phone app–delivered curricula [42,45,47,123,
134,136,137]. Another study used CBT strategies in a tailored
text messaging intervention to probe for unhelpful behaviors or
thought patterns, using information collected from the patient
[55].
B.9. Secure Medication Storage
Some studies used a “security” component designed to prevent
overuse or diversion, or prevent theft, of medication (n=3). All
3 of these studies were in opioid use disorder populations
receiving buprenorphine [65,70,71] and used a secure locked
pill dispenser. In 2 studies, doses were only available during a
3-hour window each day and were taken under the supervision
of a nurse. In one study, the dispenser released a daily dose of
medication via an access code transmitted during a remote
check-in with a mobile recovery coach [65].
B.10. Contingency Management
Finally, some studies (n=6) included a contingency management
or incentive system which involved prizes or rewards [67-69,
93,118,125]. We did not count studies as having a “contingency
management” component if the payment or rewards were given
merely for study participation; the incentives had to be built
into the overall system and specifically incentivize adherence
behaviors or comply with adherence-monitoring protocols. Most
of these systems took the form of virtual points which were
earned based on specific behaviors, tracked through mobile or
Web apps, and could be redeemed for cash. In 3 of these, points
were earned for scanning a barcode or sending photos or videos
for adherence monitoring purposes [67-69], whereas others were
earned by completing education materials, responding to
messages, or checking in to adherence enhancement systems
[93,118,125].
Multicomponent Interventions
Multicomponent interventions were those that used multiple
intervention components in tandem. Below are tables (Tables
1-4) for the 4 most common disorder contexts (substance use
disorder, depression, schizophrenia spectrum, and bipolar
disorder) which show the multicomponent apps with at least 4
separate components. We use our framework to categorize and
decompose the interventions based on which components they
include.
Table 1. Comparison of multicomponent interventions for schizophrenia spectrum disorders with 4 or more components, by presence or absence of
particular components.
System componentsaSource
B.10B.9B.8B.7B.6B.5.2B.5.1B.4B.3B.2B.1A.9A.1-8
—————————c✓✓✓✓bAschbrenner (2016) [54]
——✓✓———————✓✓Beebe (2014) [50]
————✓✓—✓—✓——✓Ben-Zeev (2014) [139]
————✓—✓—✓✓——✓Bickmore (2010) [140]
——✓——————✓—✓✓Granholm (2012) [55]
—————✓✓————✓✓Kane (2013) [63]
✓—✓—✓✓✓✓—✓✓✓✓Kreyenbuhl (2016) [12]
————✓✓————✓✓✓Ruskin (2003) [105]
———✓—✓—✓—✓—✓✓Stentzel (2016) [53]
✓————✓——✓—✓✓—Xu (2016) [125]
aA.1-8: Adherence data collection. A.9: Collection of related data. B.1: Adherence reminders. B.2: Supportive messages. B.3: Social network interventions.
B.4: Facilitating care team contact. B.5.1: Data feedback to patient. B.5.2: Data feedback to clinician. B.6: Education. B.7: Comprehensive mental health
care. B.8: Adherence-targeted psychotherapy. B.9: Secure medication storage. B.10: Contingency management.
b✓: Component is present.
c—: Component is not present.
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Table 2. List of multicomponent interventions for bipolar disorder with 4 or more components, by presence or absence of particular components.
System componentaSource
B.10B.9B.8B.7B.6B.5.2B.5.1B.4B.3B.2B.1A.9A.1-8
—————✓✓————c✓✓bFaurholt-Jepsen (2014) [44]
——✓—✓✓✓✓✓——✓✓Lauder (2017) [42]
✓———✓✓✓—————✓Sajatovic (2015) [93]
——✓—✓————✓—✓✓Wenze (2014) [136]
aA.1-8: Adherence data collection. A.9: Collection of related data. B.1: Adherence reminders. B.2: Supportive messages. B.3: Social network interventions.
B.4: Facilitating care team contact. B.5.1: Data feedback to patient. B.5.2: Data feedback to clinician. B.6: Education. B.7: Comprehensive mental health
care. B.8: Adherence-targeted psychotherapy. B.9: Secure medication storage. B.10: Contingency management.
b✓: component is present.
c—: component is not present.
Table 3. Comparison of multicomponent interventions for substance use disorder with 4 of more components, by presence or absence of particular
components.
System componentaSource
B.10B.9B.8B.7B.6B.5.2B.5.1B.4B.3B.2B.1A.9A.1-8
✓———✓—✓✓—c✓✓✓✓bGordon (2017) [68]
——✓—✓✓✓—✓✓—✓—Gustafson (2016) [123]
————✓✓—✓—✓—✓—McClure (2016) [114]
——✓—✓—✓—————✓Mooney (2007) [84]
—✓✓——✓—✓———✓✓Schuman-Olivier (2018) [65]
—✓——✓——————✓✓Sigmon (2015) [71]
——✓✓✓—✓—✓——✓—Swan (2012) [146]
——✓✓✓————✓✓——Tseng (2017) [127]
aA.1-8: Adherence data collection. A.9: Collection of related data. B.1: Adherence reminders. B.2: Supportive messages. B.3: Social network interventions.
B.4: Facilitating care team contact. B.5.1: Data feedback to patient. B.5.2: Data feedback to clinician. B.6: Education. B.7: Comprehensive mental health
care. B.8: Adherence-targeted psychotherapy. B.9: Secure medication storage. B.10: Contingency management.
b✓: component is present
c—: component is not present.
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Table 4. Comparison of multicomponent interventions for major depressive disorder with 4 or more components, by presence or absence of particular
components.
System componentaSource
B.10B.9B.8B.7B.6B.5.2B.5.1B.4B.3B.2B.1A.9A.1-8
—————✓——✓✓—c✓✓bAikens (2015) [138]
———✓✓——————✓✓Fortney (2007) [157]
——✓✓—✓—————✓✓Gervasoni (2010) [119]
—————✓✓————✓✓Lauritsen (2017) [46]
————✓✓✓✓✓——✓—Meglic (2012) [147]
————✓✓✓———✓✓✓Mohr (2015) [91]
—————✓——✓——✓✓Pfeiffer (2017) [145]
—————✓——✓——✓✓Piette (2013) [144]
———✓✓——————✓✓Rickles (2005) [152]
——✓—✓✓✓✓——✓✓✓Robertson (2006) [45]
————✓✓—————✓✓Rusche-Skolarus (2015) [51]
aA.1-8: Adherence data collection. A.9: Collection of related data. B.1: Adherence reminders. B.2: Supportive messages. B.3: Social network interventions.
B.4: Facilitating care team contact. B.5.1: Data feedback to patient. B.5.2: Data feedback to clinician. B.6: Education. B.7: Comprehensive mental health
care. B.8: Adherence-targeted psychotherapy. B.9: Secure medication storage. B.10: Contingency management.
b✓: component is present.
c—: component is not present.
Discussion
Principal Findings
Our study is the first to create a literature-driven taxonomy of
the components of adherence-monitoring methods and
adherence-enhancing interventions used across adult psychiatric
disorders. There is a proliferation of frameworks used to discuss
these technological interventions, some of which are borrowed
from nonpsychiatric adherence studies. We hope that this study
will build on existing frameworks to provide a definitive
framework for this specific context; in particular, we hope to
capture the breadth of studied interventions, and provide a
uniform vocabulary with which to discuss and compare them.
This taxonomy may prove useful during the design phase of a
new intervention, where investigators or clinicians may choose
to include relevant components from the framework to suit their
population or outcome of interest.
Although the framework was constructed bottom-up from the
literature, it does ultimately appear to parallel existing
frameworks of nonadherence behaviors. Reminders to take
medication primarily address involuntary nonadherence
concerns, whereas security and monitoring interventions often
address voluntary nonadherence [20]. Educational interventions
often aim to provide information and correct misconceptions
about disorders, medications, and side effects (addressing
perceptual nonadherence factors), whereas supportive
interventions such as social support engagement and online
community building attempt to address the well-studied
association between perceived social support and medication
nonadherence [163]. It is perhaps not surprising that adherence
interventions parallel perceived causes of nonadherence, but it
is reassuring nonetheless.
Many of the intervention types have been delivered using
various modalities. It is useful to draw a distinction between
the intervention type or component (eg, educational, reminder,
supportive, feedback, etc) and the modality by which it is
delivered (SMS, IVR, app, website, etc). Although certain
modalities of delivering certain interventions may ultimately
prove to have advantages over others (for instance, navigating
a mobile app may well be more acceptable than waiting for IVR
dialogues when filling out an adherence survey), it is not yet
clear from the literature whether this is the case. As technology
continues to evolve, there will no doubt be new modalities of
intervention delivery (for instance, the once prevalent studies
of IVR and telephonic interventions have largely been
supplanted in recent years by SMS text messaging, website, and
mobile phone app studies). One notable exception: the
distinction between modality and intervention type does not
apply to most data collection components (smart pill dispensers,
body fluid sampling, and digital pills) as the two are inextricably
tied.
The body of literature on this topic is growing, as reflected by
the increasing number of studies included from recent years.
However, looking at the literature from any individual
psychiatric or substance use disorder highlights the fact that the
field remains young, and most studies conducted are small-n
pilot studies. Furthermore, large RCTs are necessary to elucidate
the impact of particular interventions.
We found that most components are used transdiagnostically,
that is, they have been studied in schizophrenia spectrum
disorders, mood disorders, multiple substance use disorders,
and PTSD (ie, most psychiatric disorders which have a
pharmacologic component to therapy). Data collection
components (including smart pill dispensers, periodic self-report,
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and body fluid testing), reminders, educational interventions,
tele-health–driven counseling, and multicomponent disease
management apps have been explored in most or all psychiatric
disorders. This suggests that despite the differences in the mental
state between different disorders, and perhaps even different
primary reasons for nonadherence, there is still much to be
learned and transferred from one domain to the others.
Particularly, when designing a new intervention for clinical or
research use, investigators would do well to peruse the literature
from different psychiatric disorders for ideas and related work.
It is possible that transdiagnostic interventions (perhaps with
disorder-specific education or support modules) might ultimately
improve medication adherence in a general psychiatric
population. However, as of yet, very little transdiagnostic
research has been conducted in this field.
Multicomponent interventions, including comprehensive disease
management apps, have been studied in the majority of
psychiatric disorders. These interventions present a challenge
from a research standpoint, as it is difficult to assess the impact
of any individual component without large, factorial-design
studies. However, there may be synergistic adherence effects
from comprehensive disease management apps, in the same
way that standard psychiatric care visits address a wide variety
of adherence concerns and motivational factors. Furthermore,
if these interventions are to one day be used regularly in clinical
practice, multicomponent interventions are more practical from
an implementation standpoint.
One surprising fact is that many studies which evaluated the
effect of adherence-enhancing interventions used self-reported
adherence, or adherence as measured by a smart pill dispenser,
as the endpoint. Studies have shown that self-reported adherence
frequently overestimates true adherence [58,65,164,165]; this
fact may compromise or blur results from many of these studies.
Biological measurements and directly observed ingestion
provide far better adherence assessment, but are costly,
inconvenient, and often impractical to implement. Novel
adherence measurement systems, such as digital pills, automated
adherence monitoring, and remote direct observation, may
ultimately provide a better compromise between accuracy and
practicality in future trials. In fact, some of these novel methods
have been evaluated and used in clinical trials already. Accurate
assessment of adherence is crucial to evaluating the efficacy of
any of these interventions, and future investigators would do
well to select their adherence measurement endpoint wisely.
Strengths and Limitations
The strengths of our study include the breadth of the topic area
and the comprehensive coverage of all types of interventions,
as well as the literature-guided taxonomic framework. Our tables
of multicomponent interventions further show the utility of this
transdiagnostic framework to decompose and categorize
interventions across all adult mental health and substance use
disorders. However, our study is limited by this same breadth;
we were unable to conduct a quantitative synthesis or formal
meta-analysis of all included studies given the wide variety of
interventions, populations, and outcomes. In the future, we plan
to build off of this study and conduct more focused comparisons
of specific topic areas.
Conclusions
In conclusion, we provide a systematic review of the literature
on technological interventions for medication adherence and
monitoring in mental health and substance use disorders; we
then use the included studies to develop a literature-driven
transdiagnostic framework of intervention components. We
hope this will help guide future research in the field and
ultimately lead to further clinical applications.
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